- Open Access
Dendritic cell vaccines containing lymphocytes produce improved immunogenicity in patients with cancer
© Frank et al.; licensee BioMed Central Ltd. 2014
- Received: 29 September 2014
- Accepted: 21 November 2014
- Published: 5 December 2014
Dendritic cells are currently under investigation for their ability to generate anti-cancer immune responses. No consensus has been reached as to the optimal method of dendritic cell vaccine preparation and is a barrier to success in the field.
Over a course of three separate dendritic cell vaccine studies to treat cancer, we tested two different methods for preparing dendritic cells from peripheral blood mononuclear cells: adherence and antibody-selected CD14+ cells.
Surprisingly, we found that patients who received dendritic cell vaccines generated by the adherence method mounted increased T cell proliferation in response to vaccination. This difference could not be accounted for by dendritic cell vaccine dose, cell surface phenotype or dendritic cell function in vitro. One notable difference between the two vaccine preparation methods was that the dendritic cell vaccine cultures generated by the adherence method contained up to 10% lymphocytes, and these lymphocytes were proliferating and producing IFNγ in response to antigen in vitro at the time of administration.
Enhanced immunogenicity of adherence dendritic cell vaccinations may be due to the presence of lymphocytes during dendritic cell culture.
- Dendritic cells
Dendritic cells (DCs) are potent antigen presenting cells (APCs), which prime and activate CD4 helper  and CD8 cytotoxic killer T cells  and are therefore useful for initiating cancer specific immune responses. In fact, at the time of this writing, there are 417 studies listed on clinicaltrials.gov retrieved with the search terms, “dendritic cell” and “cancer”. Despite 20 years of DC vaccine trials, clinically meaningful responses have been sparse. In the search for more potent DC vaccines, different methods of precursor isolation, cell differentiation, antigen pulsing, maturation and the use of adjuvants are being evaluated. While the use of peripherally circulating monocytes as precursors and IL-4 and GM-CSF for differentiation have become an accepted standard ,, other areas of DC vaccine production remain highly variable ,.
In our own studies, we have explored the use of apoptotic tumor cells as a source of antigen for DCs. This concept arose from the finding that patients with paraneoplastic neurologic disorders (PND) can exhibit potent, naturally occurring tumor immunity and harbor antigen specific T cells to neuronal antigens . At the same time, while DCs are required to initiate de novo T cell responses, the source of antigen for the DCs was unknown, as DCs do not express the neuronal PND antigens. These observations, together with those of Rosen and colleagues regarding the effects of UV irradiation on the packaging of Lupus auto antigens into membrane-bound bodies , led us to the hypothesis that PND antigens were transferred from apoptotic tumor cells to the phagocytic DCs, and then presented to naïve T cells to trigger a potent immune response . This hypothesis was borne out with a model antigen (influenza) and with PND antigen (cdr2)  establishing a basis for the phenomenon of cross-priming proposed by Bevan ,.
Here we tested the immunogenicity of DCs presenting apoptotic tumor cells in patients with cancer, using 2 different methods of isolating DC precursors: adherence of peripheral blood mononuclear cells (PBMCs) to plastic (Adherence DCs) and selection of CD14+ cells using antibody-conjugated beads by CliniMACS (Selected DCs). In all studies, vaccines were prepared by culturing DC precursor cells with IL-4 and GM-CSF for 6 days, after which immature DCs (iDCs) were cultured with apoptotic tumor cells and treated with maturation stimulus cocktail of TNF-α, prostaglandin E2, plus or minus CD40L. Our first clinical trial of a DC vaccine treatment for prostate cancer included 24 patients who were treated with Adherence DCs pulsed with apoptotic LNCaP, a prostate cancer cell line . Proliferation responses were assessed by 3H thymidine incorporation assay pre- and post-vaccination and responses to the prostate cell lines LNCaP and PC3 were determined. Treatment induced a statistically significant increase in T cell proliferative responses to both prostate tumor cell in vitro.
In a second follow up trial, in an effort to make a more potent vaccine, two modifications were made to the vaccine. First, DCs were made using the selection method, assuming that there may be benefits to using a purer vaccine and second, a different prostate cancer cell line, PC3, was used to pulse the DCs. In our first study in which patients were vaccinated with DC/LNCaP, post-vaccination proliferation responses to PC3 (to which patients were not vaccinated) were equivalent to LNCaP. Though this was unexpected because the PC3 cells do not express known prostate cancer antigens such as PSA and PSMA, this result led us to hypothesize that PC3 is a more immunogenic cell line. Therefore, in a follow up study, seven patients were enrolled and vaccinated with Selected DCs pulsed with apoptotic PC3. Surprisingly, as we shall describe, the lymphocyte proliferation responses post-vaccination were markedly lower than that had been previously observed in the first study. This difference could not be explained by the amount of vaccine administered or the maturation status of the DCs. However, it was not clear whether this observation was due to the change in prostate cancer cell line used (LNCaP versus PC3) or the change in the method of DC preparation (Adherence versus Selected). To test this, we enrolled 3 subsequent patients who were given Adherence DC pulsed with PC3 to assess whether the change in the method of DC preparation was the cause of the difference in proliferation. Here, we compare in vitro phenotypic and functional similarities and differences between the two vaccine preparation methods.
Patients and study design
Two separate DC vaccination studies were conducted for prostate cancer patients, the first using apoptotic LNCaP cells, as reported previously , and the second using apoptotic PC3 cells. Patients in the first study were vaccinated with DCs pulsed with LNCaP (DC/LNCaP) and DCs pulsed with LNCaP transfected with influenza M1 protein (DC/LNCaP-M1) . In the second study patients were vaccinated with DCs pulsed with PC3 (DC/PC3) and DCs pulsed with PC3 transfected with influenza M1 (DC/PC3-M1). The ratio of DCs to apoptotic LNCaP or PC3 tumor cells was 1:1. In both studies, the acceptable dose range was 1-106 DCs of each type at each time point, regardless of the method of DC preparation. Patients in both studies were also given DCs pulsed with KLH (DC/KLH) as a control antigen. Initial vaccination was followed by 3 booster vaccine immunizations, each 2 weeks apart, administered subcutaneously. In both studies, leukocytes for immunomonitoring were collected by leukapheresis at baseline and again 6 weeks after the last booster.
In a third study, patients with primary brain tumors were vaccinated with DCs pulsed with autologous apoptotic tumor cells and DC/KLH. In this study, both the number of boosters and the timing of the post-vaccination leukapheresis were different from the first 2 studies. Patients were vaccinated with either 2 or 3 doses every 3 weeks intradermally and leukapheresed 2 to 3 weeks after the 2nd dose. Here, we report only the patients’ responses to DC/KLH as relevant and not the responses to the DC vaccine to brain tumor. In all 3 studies, the first dose of DC administered was “fresh” and all subsequent booster doses were thawed doses. All studies were conducted at Rockefeller University Hospital after Institutional Review Board approval. Written consent was obtained from all patients. Study identifiers on clinicaltrials.gov were: NCT00289341, NCT00345293, and NCT00893945.
Adherence method of dendritic cell vaccine preparation (Adherence DCs)
DCs were prepared as previously described . Briefly, leukapheresates were placed over lymphocyte separation media and the buffy layer was collected and washed. PBMCs were then plated in RPMI-1640 supplemented with 1% autologous plasma and allowed to adhere at 37°C. After 1 hour, the non-adherent cells were removed. The adherent cells were differentiated in RPMI-1640 supplemented with 1% autologous plasma, GM-CSF (Genzyme) and IL-4 (R & D Systems) over 6 days, at which point they are non-adherent and considered immature DCs. LNCaP and PC3 cells were obtained directly from American Type Cell Culture (CRL-1740 and CRL-1435) and cell banks were established as described . LNCaP or PC3 cells were UV irradiated and cultured with immature DCs at a 1:1 ratio with PGE2 (Sigma) and TNFα (R & D Systems, Miltenyi) over 36-48 hours. A subset of immature DCs was cultured with KLH (biosyn). The cells were harvested on the 8th day, washed and resuspended in 5% dimethyl sulfoxide and 10% human serum albumin (HSA, Grifols) in normal saline for freezing or administration.
Selection method of dendritic cell vaccine preparation (Selected DCs)
Leukapheresates were washed with PBS/EDTA supplemented with 2% HSA, incubated with CD14 MicroBeads (Miltenyi Biotec) for 15 minutes then washed. CD14+ cells were isolated using the CliniMACS System (Miltenyi Biotec). Positively selected cells were washed and plated in RPMI-1640 supplemented with 1% autologous plasma, GM-CSF (Genzyme) and IL-4 (R & D Systems) over 6 days. Cells were pulsed with tumor cells, matured and harvested in the same manner as Adherence DCs.
Lymphocyte proliferation assay
Lymphocyte proliferation responses, pre- and post-vaccination, were measured by 3H-thymidine incorporation assays as previously described  with the following changes. APCs were either pre-vaccination CD14+ cells or DCs. 3H-thymidine was added for the last 20 hours of culture. Results are presented as average count per minute (CPM) of 3 to 6 replicate wells.
Phenotyping by flow cytometry
As part of release criteria testing, DCs were counted and stained with HLA-DR, CD14, CD83 antibody (Becton Dickinson) and propidium iodide (Serologicals). For additional phenotyping, cells were stained with CD86, CD40, CCR7, CD4, CD8, CD69, and CD19 antibody (Becton Dickinson). Data was acquired on the FACSCalibur (Becton Dickinson) or MACSQuant VYB (Miltenyi Biotec) and data were analyzed using FlowJo software.
Immature Selected or Adherence DCs were stained with HLA-DR-APC and cultured with apoptotic PKH26 stained allogeneic lymphocytes with or without EDTA for 24 hours. Analysis was restricted to HLA-DR+ cells and the phagocytosis of apoptotic cells by DC groups were identified by positive PKH26 dye staining.
Allogeneic mixed leukocyte reaction (Allo-MLR)
As previously described , DCs were cultured with the non-adherent fraction of allogeneic PBMCs.
Supernatants of Adherence and Selected DCs were assessed for the presence of cytokines using the Meso Scale Discovery Human ProInflammatory 9-Plex plate and read on the SECTOR Imager (Meso Scale Discovery). DCs were prepared using each of the 2 methods from 3 donors.
The IFNγ ELISPOT assay was done as previously described  with the following modifications. Influenza-infected DCs (DCF) were used to elicit influenza-specific IFNγ responses. Adherence DC vaccine preparations were harvested on day 8 and re-plated on an IFNγ ELISPOT coated plate at a density of 25,000 lymphocytes/well.
Dextramer staining and intracellular flow cytometry analysis
PBMCs or Adherence DC preparations from A0201 donors were co-cultured with apoptotic 3T3 (DC/ctrl) or apoptotic influenza-infected 3T3 cells (DC/flu) for 5 hours in GolgiStop (BD Bioscience) before staining with APC-conjugated A0201 Influenza-M1 dextramer (GILGFVFTL, Immudex) followed by CD8-FITC (BD Bioscience). Cells were fixed and permeabilized (Cytofix/Cytoperm, BD Bioscience) as per manufacturer’s protocol. Intracellular cytokine staining was performed using IFNγ − PE (BD Bioscience) followed by flow cytometry analysis.
To evaluate the difference between proliferation responses between the patients given Selected DCs and Adherence DCs, the Mann-Whitney test was used. This test was also used to describe differences in the number and phenotype of the 2 types of DCs given. The paired t-test was used to describe differences in all other assays. P-values less than 0.05 were considered statistically significant.
Adherence DCs elicit increased proliferation of lymphocytes post-vaccination
This observed difference in immunogenicity was not anticipated. Therefore, we confirmed this by pooling data from other DC vaccine trials conducted by our laboratory, including the previously reported study in prostate cancer patients using DC/LNCaP and an additional DC vaccine study of patients with primary brain tumors. Since the tumor type was different between these studies, tumor specific responses could not be reasonably compared. However, all patients were vaccinated with DC/KLH made with either Selected or Adherence DCs, therefore, proliferation responses to KLH were examined. There were a total of 10 evaluable patients who received Selected DC/KLH and 31 patients who received Adherence DC/KLH. The vaccination induced significantly higher lymphocyte proliferation responses to KLH in patients that received Adherence DCs than those that received Selected DCs (Figure 1B; p = 0.023). No difference was observed in the proliferative lymphocyte responses to negative control APCs (not pulsed with antigen, p = 0.576). This result indicates that Adherence DCs consistently elicit higher immunogenicity even in different populations of cancer patients.
Number and phenotype of DCs administered
Median number of DCs administered per patient
no. x 106
Phenotype of DCs administered (median)
Median number of DC/KLH administered per patient in all three studies
no. x 106
Phenotype of DC/KLH administered in all three studies (median)
In vitro assays of DC phenotype and function do not predict differences in immunogenicity
We next assayed the functional ability of both DC types in an allo-MLR assay. Allogeneic lymphocytes were cultured with Adherence or Selected DCs prepared from PBMC of the same donor. The proliferative response of allogeneic lymphocytes to Adherence DC was not different than their response to Selected DC (Figure 2C, p = 0.483). We then tested the ability of the DC groups to stimulate lymphocyte proliferation in an antigen specific manner. Selected or Adherence DCs were co-cultured with either apoptotic 3T3 cells infected with influenza (DC/flu) or uninfected apoptotic 3T3 cells (DC/ctrl). DC/flu or DC/ctrl were then cultured with syngeneic lymphocytes. Both the Selected and Adherence DCs strongly stimulated influenza-specific lymphocyte proliferation (Figure 2D, p = 0.082 at peak proliferation), again pointing to a similar profile of DC function. Lastly, we assessed the differences in DC ability to induce an IFNγ response in T cells in an antigen specific manner. DC (DC) or influenza infected DC (DCF) were co-cultured with either CD4 or CD8 T cells in an ELISPOT assay. Again, both groups of DCs were able to induce a comparable CD4 and CD8 T cell IFNγ response to influenza (Figure 2E, p = 0.250 and p = 0.822 respectively). In summary, these assays indicate that there is no detectable difference in DC number, phenotype or function that could account for the observation that Adherence DCs produced increased immunogenicity in patients with cancer.
Lymphocytes in Adherence DC vaccine preparations are activated and proliferating
DC vaccines prepared by adherence support antigen specific lymphocyte proliferation and activation
Since patient vaccines were prepared by culture of immature (Day 6) DCs with apoptotic tumor cells, we hypothesized that the activated lymphocytes in Adherence DC cultures may expand in an antigen specific manner to apoptotic tumor cells. In this scenario, Adherence DC vaccines could contain an expanded population of tumor cell-specific, activated lymphocytes in addition to DC loaded with tumor cell antigen. Since we did not have enough cancer patient derived specimens to test this directly, we tested the more general hypothesis that lymphocytes contained in Adherence DC preparations proliferate in an antigen specific manner to antigens added to DC cultures on Day 6.
The discovery reported here that a common current method of preparing DCs for clinical vaccine, based on a CD14 selection strategy designed to produce purer populations of DCs, produced antigen-specific T cells with reduced proliferative capacity, was entirely unexpected. A priori, it was hypothesized that purer populations of DCs would be a more robust vaccine strategy. Exploring the mechanism for this difference revealed that DCs prepared by the two methods were comparable in their phenotype and function. We found that the primary difference between the two DC vaccine preparations were the presence of “bystander” lymphocytes in the “less pure” Adherence vaccine preparations; interestingly, we found that not only did these lymphocytes survive in the DC culture but also took on an activated and proliferating phenotype.
One hypothesis is that these activated and proliferating lymphocytes were interacting directly with the DCs to confer Adherence DCs greater potency in vivo compared to Selected DCs. For example, it has been shown that survival of DCs can be increased through the TRANCE/TRANCE receptor interaction between a T cell and DC by up-regulation of Bcl-XL expression in the DC . It is possible that the presence of activated T cells in the Adherence DC cultures promoted their survival in vivo leading to prolonged antigen-presentation and the increased post-vaccination proliferation we observed in our studies (Figure 1). Further, Berk, et al. showed that iDCs matured with expanding and activated lymphocytes induced greater IL-12p70 and CXCL10 compared to those matured with the conventional cytokine cocktail including TNF-α, IL1, IL6 and PGE2 . Since Adherence DCs are grown with a small number of expanding and activated lymphocytes, these lymphocytes could have a similar enhancing effect on the DCs that potentially contributed to the boosted immunogenicity post-vaccination.
Adherence DC vaccines also contain many CD19+ CD83+ B cells. CD83 is an early activation marker for B cells induced by interaction with activated T cells through CD40 ligation ,. Activated CD83+ B cells are capable of effective tumor-antigen presentation via MHC II  and it is possible that B cells in the Adherence DC vaccine potentiate immunogenicity. Moreover, some subset of the immune cells activated by Adherence DCs in vitro, including T cells and B cells, might reasonably be expected to be tumor antigen specific, a potentially clinically important observation.
The site of DC administration may be acting as a nidus for in vivo lymphocyte recruitment. It has been described that the great majority of DCs administered do not migrate to the draining lymph node but remain at the site of injection . Further, it has been shown that DC/CD4 T cell interactions create local MIP-1α and MIP-1β gradients that attract naïve CD8 T cells to lymph nodes . In the work presented here, we find that lymphocytes in Adherence DC cultures expand and become activated. It is possible that tumor vaccines that contain both DCs and ex-vivo activated lymphocytes could incite local inflammation, recruiting additional lymphocytes in vivo through such a chemokine gradient even without trafficking to the lymph node.
There are a number of limitations to this work. First, we did not explore what components of the lymphocytes present in the vaccine are necessary for the increased proliferation seen in patients ex vivo. Further investigation with additional patients with prostate cancer given different iterations of the vaccine preparation, such as one that contains DCs and CD3+ cells but no CD19+ cells and another that contain DCs with CD19+ cells but no CD3+ cells, for example, are necessary to address this issue. Secondly, we only show head to head comparison made between antigen-specific Adherence and Selected DCs pulsed with apoptotic PC3 cells. It is possible that this difference in immunogenicity is only present under these conditions. We did not explore in detail whether similar differences would be present under other conditions such as with use of alternative sources of antigen, maturation cocktails, route of administration, or in other cancer types. Such investigations are needed to know whether this is a generalizable finding.
DC cancer vaccine trials have resulted in varied immunological and clinical responses . It is becoming increasingly clear that DCs may require adjuvants and this is demonstrated by the recent breakthroughs using CTLA4 and PD1 blockade ,. While CD14 magnetic selection generates a highly pure population of precursor monocytes, the data presented here demonstrate that purity may actually hinder potency. Since there was no detectable difference in the cell surface phenotype or in vitro function of Adherence and Selected DC besides the presence of activated lymphocytes, we propose that these lymphocytes provide a needed adjuvant effect. Of note, the only DC tumor vaccine approved by the FDA, Sipuleucel-T, is generated by isolating cells with density gradient centrifugation and is therefore highly unlikely to contain DCs exclusively. It is possible that the activity of this agent is in part due to the presence of activated lymphocytes . Future studies will focus on dissecting which signals from activated lymphocytes are necessary and sufficient to optimize DC vaccines.
A surprising difference found in the immunogenicity of DC cancer vaccines made by two different methods of DC preparation prompted us to look into the underlying causes. We found that the dose of DCs administered, DC phenotype, and viability was similar in both vaccine types given. In vitro DC function as assessed by allo-MLR and proliferation assays were also similar. However, we show that DCs generated by the Adherence method are accompanied by proliferating and activated lymphocytes. We hypothesize that the presence of activated lymphocytes may contribute to the enhanced responses seen in patients given vaccine made using this preparation method. This is an important finding, given the variety of methods used in preparing DC vaccine studies and the mixed post-vaccination responses seen. As we evaluate DC vaccines in the future, it is imperative that we consider methods of DC preparation and how this may play a role in post-vaccination responses. Further investigation is warranted with more patients and with other variables, as this finding could have important ramifications for future DC vaccine preparation strategies.
This work was supported by Dextra Baldwin McGonagle Foundation, Inc., Emerald Foundation, Inc., Sohn Foundation and by the National Center for Advancing Translational Science, National Institutes of Health and the Clinical and Translational Science Award Program (8 UL1 TR000043). RBD is a Howard Hughes Medical Institute investigator. DEO was supported by Rockefeller University Center for Clinical and Translational Science (KL2 TR000151) and by the Beth and Ravenel Curry Clinical Scholarship. Funding sources did not have a role in the design, in the collection, analysis, and interpretation of data, in the writing of the manuscript, or in the decision to submit the manuscript for publication. We thank members of the Darnell laboratory for critical discussion and review of the manuscript and members of the Rockefeller University Hospital Nursing Staff for their compassionate care of the study participants.
- Ingulli E, Mondino A, Khoruts A, Jenkins MK: In vivo detection of dendritic cell antigen presentation to CD4(+) T cells. J Exp Med. 1997, 185: 2133-2141. 10.1084/jem.185.12.2133.PubMed CentralView ArticlePubMedGoogle Scholar
- Mehta-Damani A, Markowicz S, Engleman EG: Generation of antigen-specific CD8+ CTLs from naive precursors. J Immunol. 1994, 153: 996-1003.PubMedGoogle Scholar
- Sallusto F, Lanzavecchia A: Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med. 1994, 179: 1109-1118. 10.1084/jem.179.4.1109.View ArticlePubMedGoogle Scholar
- Zhou LJ, Tedder TF: CD14+ blood monocytes can differentiate into functionally mature CD83+ dendritic cells. Proc Natl Acad Sci U S A. 1996, 93: 2588-2592. 10.1073/pnas.93.6.2588.PubMed CentralView ArticlePubMedGoogle Scholar
- Jonuleit H, Kuhn U, Muller G, Steinbrink K, Paragnik L, Schmitt E, Knop J, Enk AH: Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur J Immunol. 1997, 27: 3135-3142. 10.1002/eji.1830271209.View ArticlePubMedGoogle Scholar
- Albert ML, Darnell JC, Bender A, Francisco LM, Bhardwaj N, Darnell RB: Tumor-specific killer cells in paraneoplastic cerebellar degeneration. Nat Med. 1998, 4: 1321-1324. 10.1038/3315.View ArticlePubMedGoogle Scholar
- Casciola-Rosen LA, Anhalt G, Rosen A: Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. J Exp Med. 1994, 179: 1317-1330. 10.1084/jem.179.4.1317.View ArticlePubMedGoogle Scholar
- Darnell RB: Onconeural antigens and the paraneoplastic neurologic disorders: at the intersection of cancer, immunity, and the brain. Proc Natl Acad Sci U S A. 1996, 93: 4529-4536. 10.1073/pnas.93.10.4529.PubMed CentralView ArticlePubMedGoogle Scholar
- Bevan MJ: Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay. J Exp Med. 1976, 143: 1283-1288. 10.1084/jem.143.5.1283.View ArticlePubMedGoogle Scholar
- Carbone FR, Bevan MJ: Class I-restricted processing and presentation of exogenous cell-associated antigen in vivo. J Exp Med. 1990, 171: 377-387. 10.1084/jem.171.2.377.View ArticlePubMedGoogle Scholar
- Frank MO, Kaufman J, Tian S, Suarez-Farinas M, Parveen S, Blachere NE, Morris MJ, Slovin S, Scher HI, Albert ML, Darnell RB: Harnessing naturally occurring tumor immunity: a clinical vaccine trial in prostate cancer. PLoS One. 2010, 5 (9): e12367-10.1371/journal.pone.0012367. doi:10.1371/journal.pone.0012367PubMed CentralView ArticlePubMedGoogle Scholar
- Orange DE, Jegathesan M, Blachere NE, Frank MO, Scher HI, Albert ML, Darnell RB: Effective antigen cross-presentation by prostate cancer patients’ dendritic cells: implications for prostate cancer immunotherapy. Prostate Cancer Prostatic Dis. 2004, 7: 63-72. 10.1038/sj.pcan.4500694.View ArticlePubMedGoogle Scholar
- Wong BR, Josien R, Lee SY, Sauter B, Li HL, Steinman RM, Choi Y: TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor. J Exp Med. 1997, 186: 2075-2080. 10.1084/jem.186.12.2075.PubMed CentralView ArticlePubMedGoogle Scholar
- Berk E, Kalinski P: Lymphocyte-polarized DC1s: Effective inducers of tumor-specific CTLs. Oncoimmunology. 2012, 1: 1443-1444. 10.4161/onci.21295.PubMed CentralView ArticlePubMedGoogle Scholar
- Lapointe R, Bellemare-Pelletier A, Housseau F, Thibodeau J, Hwu P: CD40-stimulated B lymphocytes pulsed with tumor antigens are effective antigen-presenting cells that can generate specific T cells. Cancer Res. 2003, 63: 2836-2843.PubMedGoogle Scholar
- Kretschmer B, Kuhl S, Fleischer B, Breloer M: Activated T cells induce rapid CD83 expression on B cells by engagement of CD40. Immunol Lett. 2011, 136: 221-227. 10.1016/j.imlet.2011.01.013.View ArticlePubMedGoogle Scholar
- Ridolfi R, Riccobon A, Galassi R, Giorgetti G, Petrini M, Fiammenghi L, Stefanelli M, Ridolfi L, Moretti A, Migliori G, Fiorentini G: Evaluation of in vivo labelled dendritic cell migration in cancer patients. J Transl Med. 2004, 2: 27-10.1186/1479-5876-2-27.PubMed CentralView ArticlePubMedGoogle Scholar
- Castellino F, Huang AY, Altan-Bonnet G, Stoll S, Scheinecker C, Germain RN: Chemokines enhance immunity by guiding naive CD8+ T cells to sites of CD4+ T cell-dendritic cell interaction. Nature. 2006, 440: 890-895. 10.1038/nature04651.View ArticlePubMedGoogle Scholar
- Butterfield LH: Dendritic cells in cancer immunotherapy clinical trials: are we making progress?. Front Immunol. 2013, 4: 454-10.3389/fimmu.2013.00454.PubMed CentralView ArticlePubMedGoogle Scholar
- Jochems C, Tucker JA, Tsang KY, Madan RA, Dahut WL, Liewehr DJ, Steinberg SM, Gulley JL, Schlom J: A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: immune correlates. Cancer Immunol Immunother. 2014, 63: 407-418. 10.1007/s00262-014-1524-0.View ArticlePubMedGoogle Scholar
- Perez-Gracia JL, Labiano S, Rodriguez-Ruiz ME, Sanmamed MF, Melero I: Orchestrating immune check-point blockade for cancer immunotherapy in combinations. Curr Opin Immunol. 2014, 27: 89-97. 10.1016/j.coi.2014.01.002.View ArticlePubMedGoogle Scholar
- Small EJ, Fratesi P, Reese DM, Strang G, Laus R, Peshwa MV, Valone FH: Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol. 2000, 18: 3894-3903.PubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.